PLACIDE study	Research number:					Pat	ient initia	uls:		
	PLACIDE st	udy Ca	ase F	Report	Forn	n (CRF)				
A multicentre, rand bifidobacteria in the <i>difficile</i> diarrhoea is antibiotics.	ne prevention of an	ntibioti	ic-ass	sociate	d diai	rrhoea an	d Closti	ridiı		
Front sheet: Check and 2 and file in re				-			data. De	etacl	n pages 1	
Study number iss	ued at recruitmen	t :]	PLAC	IDE					
While in the study	the participant wi	ill be ic	denti	fied by	this	study nur	nber			
Is the patient eligi	ible? check inclu	sion / e	exclu	sion cr	iteria	(page 2)	Y/N			
Patient details										
Name										
Hospital number							Age			
Address and post code										
Telephone:	Home:				Wo	rk:				
	Mobile:				Em	nail:				
Details of next of Name	kin									
Relationship: Spou	use-1; Son/daught	er -2; F	Relati	ive-3; (Carer-	-4; Other	-5			
Address and post code										
Telephone:										
GP details Name										
Address and post Code										
Telephone:										

Date completed

signed

1

PLACIDE s	study	Research number.					Patient initials:	
Inclusion	criteria	*: code as Y / N						
• Ag	ge ≥ 65 y	vears						
• On	ne or mo	re doses of antib	oiotic w	ithin l	ast 7	days o	or starting antibiotic today	
• Co	nsultant	approval for in	vitation	to joi	n stud	ly		
Exclude if	f "No" t	o any of these o	uestio	ns				
Exclusion	criteria	*: code as Y / N	1					
• D	iarrhoea	now ¹			•		nown compromised gut good supply ⁶	
• In	nmunoc	ompromised ²			•	Na siti	so-jejunal feeding tube <i>in</i>	
	ctive inti	flammatory bow	el		•		lverse reaction to previous obiotics	
• P1	rosthetic	heart valve			•		ntinues on other live eterial food preparations	
• St	uspected	l acute pancreati	tis ⁴		•	<i>C</i> .	difficile in past 3 months	
• R in	equires intensive	high dependency care ⁵	y or					
Exclude	if "Yes'	' to any of these)					
 Co dis Re Ab No 	empromi sseminat equired s edomina ot admiss	sed immunity su ed cancer / chen pecific treatmen I pain + serum a sion just for obse	officien nothera t in pas mylase ervation	t to re py, Al t 12 n /lipase n (e.g.	quire IDS, knonths e>3 Upost of	isolat mown s JLN cardia	rt 5 - 7) in a 24 hour period ion and barrier nursing (e.g i immunodeficiency disease c surgery) els or coeliac axis	,•
*If in dou	bt, disc	uss with Projec	t Mana	iger o	r Res	earch	Clinician <i>before</i> recruitn	nent
Date comp	oleted			/			signed	2

PLACIDE study Research number:	Patient initials:
Data entry clerks: Enter the following data into the PLAC.	IDE CRF database
Date person recruited into PLACIDE study	
If assent, relationship to patient:	(see previous)
Demography Gender: Male-1; Female-2	
DOB	/ /
Race: White-1; Black-2; Asian-3; Chinese-4; Other-5 and	specify:
Weight (kg)	
Average number cigarettes / day	
Average number units alcohol / week*	
*Approx units: 1 pint beer – 2; 1 standard glass wine – 2;	small measure spirits – 1.
This admission	
Date of hospital admission	//
Initial diagnosis / reason for admission	
Admitted from home-1, residential care-2, other hospital-3	3, other -4
If other, details:	
Previous gastrointestinal surgery? Y / N	
If Yes – specify operation(s) done and year performed:	
Co- morbidity (Y / N or 9 if not known):	
Hypertension Asthma	Diabetes
COPD Renal Disease	Irritable bowel syndrome
Dementia or Alzheimer's disease	Other co-morbidity*
*If Yes - specify:	
Date completed / / /	signed 3

PLACIDE study Research number: Patient initials:
Other information
Current stool frequency / week stool consistency (Bristol chart)
No. hospital admissions in last 8 weeks NGT in situ: Y / N
Live bacteria consumed in last 2 weeks*
* includes live yogurts (e.g. Actimil, Yakult), probiotics bought from health food shops, over internet
STUDY intervention
Day 1 is the first day that the person <i>had the opportunity</i> to take the study intervention and is either the same day as the recruitment day or the next day.
Day 1 date / / / / / / / / / / / / / / / / / / /
Start time of study intervention (nearest hour; 24 hour clock)*
*record 99 if not known; 88 if not taken
End of study summary: Complete at the end of follow-up
Final classification of participant
No diarrhoea-1; AAD-2; <i>C. difficile</i> diarrhoea-3; other cause of diarrhoea-4; died-5; withdrawn-6.
Outcome date (death, withdrawal, end of FU):
Date of hospital discharge: / / / /
Discharge and outcome dates same if participant dies or is withdrawn in hospital
If withdrawn:
High dependency or ITU care-1; pancreatitis-2; bowel ischaemia-3; other – 4 and details:
Notes:
Please check that all data is accurate and complete. Then submit form to Data Manager for checking prior to data entry
Date completed / / / signed 4

PLACIDE study Research number:					Patient initials:	
--------------------------------	--	--	--	--	-------------------	--

Medication record: Antibiotics

Record details of any antibiotics (including single doses) that the person has taken in the 8 weeks before recruitment until the end of follow-up.

- Record as much information as possible (e.g. "middle November" = 15/11/xx)
- Route: Oral/NGT = 1; IV/IM = 2; other = 3
- Record dates as DD/MM/YY; record 88/88/88 if on-going at end of follow-up; 99/99/99 if not known
- Check that the information is complete at the end of follow-up

Antibiotic 1:	Route Dose (mg) No. doses/day
Indication:	
Start date	/ Stop date: / / / /
Antibiotic 2:	Route Dose (mg) No. doses/day
Indication:	
Start date	/ Stop date: / / / /
Antibiotic 3:	Route Dose (mg) No. doses/day
Indication:	
Start date	/ Stop date: / / /
Antibiotic 4:	Route Dose (mg) No. doses/day
Indication:	
Start date	/ Stop date: / / / /
Antibiotic 5:	Route Dose (mg) No. doses/day
Indication:	
Start date	/ Stop date: / / / /
Antibiotic 6:	Route Dose (mg) No. doses/day
Indication:	
Start date	/
Date completed	

PLACIDE study Research number: Patient initials:
Antibiotic 7: Route Dose (mg) No. doses/day
Indication:
Start date / Stop date: / / /
Antibiotic 8:
Indication:
Start date / Stop date: / / /
Antibiotic 9: Route Dose (mg) No. doses/day
Indication:
Start date / Stop date: / / /
Medication record: other drugs being taken at recruitment
Enter Y, N or 9 for don't know
■ Proton Pump inhibitor¹ ■ H₂ blockers²
AntacidsACE inhibitors
■ Anti-hypertensives ■ Aspirin (used most days)
■ Oral hypoglycaemic agents ■ NSAIDS (used most days)
■ Insulin
*If Y, name:
Examples are: lanzoprazole, omeperazole. Examples are: ranitidine, cimetidine, zantac.
Date completed / / signed 6